Paul Peng
Vice President - CMC City Therapeutics
Seminars
Tuesday 8th December 2026
Building the Next Generation of Conjugates, Ligands & Linkers for Targeted Oligonucleotide Delivery to Unlock Extrahepatic Tissues & Improve Therapeutic Efficacy
Interactive workshop exploring how developers are designing, selecting and optimizing conjugates, ligands and linkers to improve tissue-specific delivery and maximize therapeutic performance. Through expert discussion and practical case studies, attendees will evaluate the critical design decisions that influence target efficiency, manufacturability, safety and long-term platform potential.
Workshop highlights
- Evaluate the latest ligand discovery strategies, comparing established targets such as ASGPR and transferrin receptor with emerging receptor biology to identify new opportunities for tissue-specific delivery
- Explore how linker design influences conjugate performance, understanding the impact of stability, release mechanisms and pharmacokinetics on efficacy, safety and therapeutic index
- Understand the CMC and manufacturing considerations that shape successful conjugate development, including process scalability, raw material selection, technology transfer and the impact of design decisions on manufacturability and clinical supply
- Leave with a practical framework for building a competitive targeting platform, including the key scientific, translational and commercial questions partners and investors will expect your technology to answer before advancing into collaboration or development
Wednesday 9th December 2026
Industry Leader’s Fireside Chat: Tracing Antibody Engineering’s Evolution Into ADC-Style Oligo Delivery & Charting Where the Field Is Headed Next
9:00 am
Exploring how priorities have shifted across the ecosystem, from proving modality feasibility to solving delivery, scalability and commercialization challenges, and what this means for the next generation of RNA therapeutics.
- Gain insight into the evolving innovation landscape, including how changing investment priorities, strategic collaborations and platform consolidation are influencing the future direction of oligonucleotide therapeutics and partnership opportunities
- Delving into the scientific, manufacturing and strategic considerations that determine whether innovative delivery technologies successfully translate from platform concepts into approved medicines
